- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Inhibikase Therapeutics files for secondary offering of common stock | 3 | Seeking Alpha | ||
| 14.11. | Inhibikase Therapeutics GAAP EPS of -$0.65 misses by $0.17 | 2 | Seeking Alpha | ||
| 14.11. | Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity | 99 | GlobeNewswire (Europe) | -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial... ► Artikel lesen | |
| 14.11. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.10. | Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More | 45 | Insider Monkey | ||
| 22.10. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10. | Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension | 110 | GlobeNewswire (Europe) | -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and... ► Artikel lesen | |
| 14.10. | H.C. Wainwright senkt Kursziel für Inhibikase Therapeutics; behält Kaufempfehlung bei | 3 | Investing.com Deutsch | ||
| 14.10. | Inhibikase Therapeutics stock target cut by H.C. Wainwright; retains Buy rating | 1 | Investing.com | ||
| 09.10. | Why Inhibikase Therapeutics (IKT) Stock Is Up 50% Today | 1 | Benzinga.com | ||
| 09.10. | Inhibikase Therapeutics stock rises after pricing $110M private offering | 2 | Seeking Alpha | ||
| 09.10. | Inhibikase Therapeutics announces $110 million financing | 2 | Investing.com | ||
| 09.10. | Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension | 2 | GlobeNewswire (USA) | ||
| 09.10. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 16.08. | Inhibikase shares target cut, analyst retains buy rating on earnings report | 2 | Investing.com | ||
| 16.08. | Earnings call: Inhibikase Therapeutics reports Q2 financials, trial updates | 3 | Investing.com | ||
| 15.08. | Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01 | 1 | Seeking Alpha | ||
| 14.08. | Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity | 90 | GlobeNewswire (Europe) | BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor... ► Artikel lesen | |
| 14.08. | Inhibikase Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 169,96 | +0,04 % | AbbVie-Aktie: Kurs klettert leicht (170,3011 €) | An der US-amerikanischen Börse liegt die AbbVie-Aktie derzeit im Plus. Die Aktie notiert gegenwärtig bei 177,28 US-Dollar. Im US-amerikanischen Wertpapierhandel hat sich heute der Anteilsschein von... ► Artikel lesen | |
| TEVA | 16,250 | -1,22 % | Teva Pharmaceutical: Teva Takes on Antimicrobial Resistance: What You Need to Know | NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics, making infections harder to treat and increasing the risk and... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 8,616 | +0,42 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| BAUSCH HEALTH | 7,869 | +2,90 % | Bausch Health Companies Inc.: Bausch Health and Salix to Present at the American Association for the Study of Liver Disease the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis | Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)... ► Artikel lesen | |
| ORGANIGRAM | 1,438 | -1,78 % | Organigram Reports Third Quarter Fiscal 2024 Results | TORONTO--(BUSINESS WIRE)--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 5,050 | -1,94 % | Quantum Biopharma Ltd.: Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 in Australia | TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 8,950 | -3,24 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,190 | -7,00 % | Looking Into Tonix Pharmaceuticals' Recent Short Interest | ||
| NEWRON PHARMACEUTICALS | 8,250 | -0,60 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| NEKTAR THERAPEUTICS | 0,951 | -5,33 % | Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence | - NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -
SAN FRANCISCO, Nov. 18,... ► Artikel lesen | |
| COMPASS PATHWAYS | 4,240 | -0,47 % | Compass Pathways plc: Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates | Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025 COMP006 data will now be announced after 26-week time point... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 122,05 | +0,33 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract ... | Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,185 | -2,47 % | XORTX Therapeutics Inc (3): XORTX Therapeutics private placement | ||
| MADRIGAL PHARMACEUTICALS | 332,50 | -0,33 % | Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? | ||
| OPUS GENETICS | 0,952 | -1,35 % | Foundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics | The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD)
RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal... ► Artikel lesen |
INHIBIKASE THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,250 Euro und damit +11,94 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.
